Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Lachman Consultant Services Inc. mishandled filing Pharmathen SA’s application to make a generic version of the blockbuster multiple sclerosis drug Tecfidera, according to a new lawsuit.
The suit, filed Nov. 21 in the U.S. District Court for the Southern District of New York, alleges the consulting firm negligently caused Pharmathen to lose out on first-to-file exclusivity rights on generic Tecfidera. The first generic applicant to challenge the patent on a drug is eligible for six months of market exclusivity on the generic ( Pharmathen S.A. v. Lachman Consultant Services Inc. , S.D.N.Y., No. 17-cv-09127, complaint filed 11/21/17 ).
The suit is one of the first of its kind, according to a Matt Hyams, spokesman for Pillsbury Winthrop Shaw Pittman LLP, which filed the complaint for Pharmathen. Branded Tecfidera, made by Cambridge, Mass.-based Biogen Inc., is projected to generate $4 billion in 2018 sales, making the rights for six months of market exclusivity on the first generic version of the blockbuster exceedingly valuable.
Pharmathen, a Greek drug company, hired Lachman to assist it with filing an abbreviated new drug application to make a generic version of Tecfidera (dimethyl fumarate) with the Food and Drug Administration. Its complaint alleges breach of contract, gross negligence, and negligent performance of services. According to Pharmathen, Lachman didn’t submit Pharmathen’s ANDA on time, causing it to forfeit any potential marketing exclusivity rights in generic Tecfidera.
Several other generic filers filed by the required deadline, Pharmathen said, but Lachman didn’t file Pharmathen’s ANDA until a day after the deadline to be eligible for the marketing exclusivity rights.
“Lachman’s failure to file the ANDA by the required deadline is incurable, and Pharmathen has forever lost its potential first-to-file marketing exclusivity rights for a generic version of Tecfidera as a result,” the complaint said. Pharmathen estimates its loss to be “tens if not hundreds of millions of dollars of revenue.”
Pharmathen is also seeking attorneys’ fees.
Bloomberg Law contacted Westbury, N.Y.-based Lachman for comment but no one was available to respond.
To contact the reporter on this story: Dana A. Elfin in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Brian Broderick at email@example.com
The complaint is at http://src.bna.com/ut4.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)